Preface

Diane Ashiru-Oredope; John D. Perry

doi:10.1093/jac/dky160

Preface

Research output: Contribution to journal › Editorial

Original language	English
Pages (from-to)	vi1
Journal	Journal of Antimicrobial Chemotherapy
Volume	73
DOIs	https://doi.org/10.1093/jac/dky160
Publication status	Published - 1 Jun 2018

Bibliographical note

Funding Information:
In both human and economic terms, antimicrobial resistance presents an increasing global burden and the development of new antimicrobials, as well as the effective stewardship of existing agents, is critically important. DRIVE-AB (Driving re-investment in Research and Development and responsible antibiotic use) is a project composed of public and private partners from 12 countries (http://drive-ab.eu/). It is funded by the Innovative Medicines Initiative (IMI); a joint undertaking between the European Union and the European Pharmaceutical Industry Association (EFPIA). The DRIVE-AB consortium is tasked with defining responsible use of antibiotics, identifying antibiotic-related public health priorities, calculating the societal value of developing new antibiotics, and developing new economic models to promote the required innovation and sustainable use of new antibiotics.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/jac/dky160

Cite this

@article{dfdc687aa39b42ac826ce016a56fba9c,

title = "Preface",

author = "Diane Ashiru-Oredope and Perry, {John D.}",

note = "Funding Information: In both human and economic terms, antimicrobial resistance presents an increasing global burden and the development of new antimicrobials, as well as the effective stewardship of existing agents, is critically important. DRIVE-AB (Driving re-investment in Research and Development and responsible antibiotic use) is a project composed of public and private partners from 12 countries (http://drive-ab.eu/). It is funded by the Innovative Medicines Initiative (IMI); a joint undertaking between the European Union and the European Pharmaceutical Industry Association (EFPIA). The DRIVE-AB consortium is tasked with defining responsible use of antibiotics, identifying antibiotic-related public health priorities, calculating the societal value of developing new antibiotics, and developing new economic models to promote the required innovation and sustainable use of new antibiotics.",

year = "2018",

month = jun,

day = "1",

doi = "10.1093/jac/dky160",

language = "English",

volume = "73",

pages = "vi1",

journal = "Journal of Antimicrobial Chemotherapy",

issn = "0305-7453",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Preface

AU - Ashiru-Oredope, Diane

AU - Perry, John D.

N1 - Funding Information: In both human and economic terms, antimicrobial resistance presents an increasing global burden and the development of new antimicrobials, as well as the effective stewardship of existing agents, is critically important. DRIVE-AB (Driving re-investment in Research and Development and responsible antibiotic use) is a project composed of public and private partners from 12 countries (http://drive-ab.eu/). It is funded by the Innovative Medicines Initiative (IMI); a joint undertaking between the European Union and the European Pharmaceutical Industry Association (EFPIA). The DRIVE-AB consortium is tasked with defining responsible use of antibiotics, identifying antibiotic-related public health priorities, calculating the societal value of developing new antibiotics, and developing new economic models to promote the required innovation and sustainable use of new antibiotics.

PY - 2018/6/1

Y1 - 2018/6/1

UR - http://www.scopus.com/inward/record.url?scp=85048539868&partnerID=8YFLogxK

U2 - 10.1093/jac/dky160

DO - 10.1093/jac/dky160

M3 - Editorial

AN - SCOPUS:85048539868

SN - 0305-7453

VL - 73

SP - vi1

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

ER -

Preface

Bibliographical note

UN SDGs

Access to Document

Other files and links

Cite this